Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism

European Journal of Endocrinology

Volumn 157, Issue 6, 2007, Pages 709-716

  van der Klaauw, Agatha A ^a   Biermasz, Nienke R ^a   Zelissen, Pierre M J ^b   Pereira, Alberto M ^a   Lentjes, Eef G W M ^b   Smit, Johannes W A ^a   van Thiel, Sjoerd W ^a   Romijn, Johannes A ^a   Roelfsema, Ferdinand ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; ESTROFEM; ESTROGEN; RECOMBINANT GROWTH HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; HUMAN GROWTH HORMONE; IGFBP3 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTHRALGIA; ARTICLE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMOTIONAL STRESS; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMALE; FLUID RETENTION; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPITUITARISM; LOW DRUG DOSE; MENSTRUATION; MULTIPLE CYCLE TREATMENT; MYALGIA; PARALLEL DESIGN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; STEADY STATE; WEIGHT GAIN; BLOOD; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DYDROGESTERONE; ESTRADIOL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; RECOMBINANT PROTEINS; SEX HORMONE-BINDING GLOBULIN;

EID: 38349052061     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0412     Document Type: Article

References (27)

1. Giustina A & Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews 1998 19 717-797.
2. van den BG, Veldhuis JD, Frolich M & Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. Journal of Clinical Endocrinology and Metabolism 1996 81 2460-2467.
3. Cook DM, Ludlam WH & Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism 1999 84 3956-3960.
4. Johansson AG, Engstrom BE, Ljunghall S, Karlsson FA & Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. Journal of Clinical Endocrinology and Metabolism 1999 84 2002-2007.
5. Span JP, Pieters GF, Sweep CG, Hermus AR & Smals AG. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. Journal of Clinical Endocrinology and Metabolism 2000 85 1121-1125.
6. Christiansen JJ, Fisker S, Gravholt CH, Bennett P, Svenstrup B, Andersen M, Feldt-Rasmussen U, Christiansen JS & Jorgensen JO. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I. European Journal of Endocrinology 2005 152 719-726.
7. Janssen YJ, Hetmerhorst F, Frolich M & Roelfsema F. A switch from oral (2 mg/day) to transdermal (50 μg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. Journal of Clinical Endocrinology and Metabolism 2000 85 464-467.
8. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M & Ho KK. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. American Journal of Physiology. Endocrinology and Metabolism 2001 281 E1 191-E1 196.
9. Fink BJ & Christensen MS. Bioavailability of oestradiol and oestriol administered orally to oophorectomized women. Maturitas 1981 3 289-294.
10. de Vries BB, Robinson H, Stolte-Dijkstra I, Tjon Pian Gi CV, Dijkstra PF, van Doorn J, Halley DJ, Oostra BA, Turner G & Niermeijer MF. General overgrowth in the fragile X syndrome: variability in the phenotypic expression of the FMR1 gene mutation. Journal of Medical Genetics 1995 32 764-769.
11. Gibney J, Johannsson G, Leung KC & Ho KK. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. Journal of Clinical Endocrinology and Metabolism 2005 90 3897-3903.
12. Kam GY, Leung KC, Baxter RC & Ho KK. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. Journal of Clinical Endocrinology and Metabolism 2000 85 1918-1922.
13. Lissett CA & Shalet SM. The impact of dose and route of estrogen administration on the somatotropic axis in normal women. Journal of Clinical Endocrinology and Metabolism 2003 88 4668-4672.
14. Paassilta M, Karjalainen A, Kervinen K, Savolainen MJ, Heikkinen J, Backstrom AC & Kesaniemi YA. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy: relation to lipoprotein(a) levels. Atherosclerosis 2000 149 157-162.
15. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM & Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/ insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996 81 2848-2853.
16. Veldhuis JD, Evans WS & Bowers CY. Estradiol supplementation enhances submaximal feed-forward drive of growth hormone (GH) secretion by recombinant human GH-releasing hormone-1,44-amide in a putatively somatostatin-withdrawn milieu. Journal of Clinical Endocrinology and Metabolism 2003 88 5484-5489.
17. Veldhuis JD, Anderson SM, Kok P, Iranmanesh A, Frystyk J, Orskov H & Keenan DM. Estradiol supplementation modulates growth hormone (GH) secretory-burst waveform and recombinant human insulin-like growth factor-I-enforced suppression of endogenously driven GH release in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2004 89 1312-1318.
18. Ruoff WL & Dziuk PJ. Absorption and metabolism of estrogens from the stomach and duodenum of pigs. Domestic Animal Endocrinology 1994 11 197-208.
19. Scharl A, Beckmann MW, Artwohl JE, Kullander S & Holt JA. Rapid liver metabolism, urinary and bifiary excretion, and enterohepatic circulation of 16 alpha-radioiodo-17 beta-estradiol. International Journal of Radiation Oncology, Biology, Physics 1991 21 1235-1240.
20. Stomati M, Hartmann B, Spinetti A, Mailand D, Rubino S, Albrecht A, Huber J, Petraglia F & Genazzani AR. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-I levels in post-menopausal women. Journal of Endocrinological Investigation 1996 19 535-541.
21. Friend KE, Hartman ML, Pezzoli SS, Clasey JL & Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. Journal of Clinical Endocrinology and Metabolism 1996 81 2250-2256.
22. Borski RJ, Tsai W, DeMott-Friberg R & Barkan AL. Regulation of somatic growth and the somatotropic axis by gonadal steroids: primary effect on insulin-like growth factor I gene expression and secretion. Endocrinology 1996 137 3253-3259.
23. Krattemnacher R, Knauthe R, Parczyk K, Walker A, Hilgenfeldt U & Fritzemeier KH. Estrogen action on hepatic synthesis of angiotensinogen and IGF-I: direct and indirect estrogen effects. Journal of Steroid Biochemistry and Molecular Biology 1994 48 207-214.
24. Leung KC, Doyle N, Ballesteros M, Sjogren K, Watts CK, Low TH, Leong GM, Ross RJ & Ho KK. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. PNAS 2003 100 1016-1021.
25. Janssen YJ, Frolich M & Roelfsema F. A low starting dose of genotropin in growth hormone-deficient adults. Journal of Clinical Endocrinology and Metabolism 1997 82 129-135.
26. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, Woitge HW, Blum WF, Wuster C, Haack D & Ziegler R. Relationship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50- to 80-year-old men and women. Journal of Clinical Endocrinology and Metabolism 1996 81 2534-2540.
27. Leung KC, Johannsson G, Leong GM & Ho KK. Estrogen regulation of growth hormone action. Endocrine Reviews 2004 25 693-721.